Unfortunately, insufficient evidence is available on the benefits of strict glycaemic control in patients hospitalized with COVID-19 due to the fact that glycaemic management was underestimated during outbreak and the difficulties of multiple daily insulin injections and frequent point-of-care glucose testing in areas with high burden of COVID-19 patients [22,23]. The gene discussed is INS; the disease is COVID-19.